| Today’s Big NewsAug 22, 2024 |
|
September 9-12, 2024 | Philadelphia, PA Join us at Digital Pharma East, the leading event for digital innovation in the pharmaceutical industry. Dive into key topics including Digital Marketing, Data & Analytics, and Patient Engagement. Learn from industry experts, network with peers, and explore cutting-edge strategies to drive your digital initiatives forward. The clock is TICKING! Secure Your Pass!
|
|
| By Gabrielle Masson After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome Biosciences is making cuts. |
|
|
|
By Kevin Dunleavy The momentum the biopharma industry showed in the first quarter of 2024 continued into the second quarter as 21 of the industry's top 25 companies achieved year-over-year revenue increases. Once again, the dominant players were the sellers of GLP-1 diabetes and obesity drugs Eli Lilly and Novo Nordisk, which saw revenue boosts of 36% and 27%, respectively. |
By Angus Liu The FDA will hold an advisory committee meeting on Sept. 26 to consider whether approvals for checkpoint inhibitors in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma—as well as in esophageal squamous cell carcinoma (ESCC)—should be restricted based on a tumor’s PD-L1 expression. |
By Zoey Becker The company reported a new order of its smallpox and mpox vaccine, Jynneos, from an undisclosed European country. The procurement deal adds to a list of several recent orders for the company. |
|
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
By Fraiser Kansteiner While the biotech investment scene in Europe has shrunk somewhat following a COVID-19 funding boom in 2021, a new report from PitchBook suggests venture capital firms looking at opportunities across the pond could soon have more cash to spare. |
By Andrea Park As summer winds down in the U.S. and the colder months creep closer, so too does the annual respiratory virus season, when highly contagious diseases like influenza, COVID-19 and respiratory syncytial virus make the rounds. |
By Nick Paul Taylor The Medicines and Healthcare products Regulatory Agency (MHRA) has ruled Vertex broke the U.K. drug regulations with a LinkedIn post, prompting the big biotech to review its social media policies. |
By Darren Incorvaia In the decades that modern ventilation has been in use, it has contended with a serious side effect: lung injury. While the patient needs air, pushing too much of it into the lungs in the wrong way can end up causing lasting harm, including multiorgan failure and death. |
By James Waldron Novartis’ $3.2 billion deal for Chinook Therapeutics gave the Swiss Big Pharma such a taste for kidney disease-focused biotechs that it has partnered with VC firm Versant Ventures to create another company in a similar mold. |
By Zoey Becker Researchers looked at data from the 2018-2020 Ebola outbreak in the Democratic Republic of Congo to gauge the real-world benefits of using Merck's vaccine Ervebo. |
By Nick Paul Taylor BioAge Labs has appointed former GSK CEO Jean-Pierre Garnier as chair of its board of directors, bringing the pharma veteran back into the anti-aging space 16 years after he made a big bet on the sector. |
By Nick Paul Taylor Eli Lilly has expanded its partnership with Oblique Therapeutics, adding a second strand to an alliance focused on using the AbiProt platform to discover antibodies against high-value targets. |
By Fraiser Kansteiner Despite some Western drugmakers’ concerns around working with Chinese manufacturers in light of the looming BIOSECURE Act, WuXi Biologics continues to pick up a steady stream of new contracts, the company said. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we look at how healthcare companies are incentivizing consumers to more proactively take care of themselves by forming lasting healthy habits. |
|
|---|
|
|
|
Thursday, September 12, 2024 | 10am ET / 7am PT Nitrosamines, potent carcinogens, have prompted stringent regulations for their detection and control in various products. With regulatory bodies demanding robust analytical methods and risk assessments, pharmaceutical and medical devices manufacturers must stay on top of the current regulatory landscape and compliance strategies. Register now for access to the key insights you need to know. |
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
